Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
With
Sanofi
Successive cohorts of three or more patients were treated at escalating doses until a maximum tolerated dose/recommended phase 1 dose was identified. Once the maximum tolerated dose was identified, an Expansion Cohort was enrolled at that dose to further characterize safety and to explore pharmacodynamic endpoints.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cytological or histological confirmation of locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or endometrial cancer; OR, cytological or histological confirmation of locally advanced /metastatic Her2 non-overexpressing breast cancer
Eighteen years of age or above
Candidates for chemotherapy
Able to understand and sign an informed consent (or have a legal representative who is able to do so)
Measurable disease according to RECIST v1.1
ECOG Performance Score (PS) of ≤ 2
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121
You may not be if
Prior radiation therapy to \>25% of bone marrow-bearing areas
Evidence of any other active malignancy
Active infection or fever\> 38.5°C during screening visits or on the first scheduled day of dosing
Symptomatic CNS disease
Known hypersensitivity to any of the components of MM-121 or who have had hypersensitivity reactions to fully human monoclonal antibodies
Received treatment, within 30 days prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state
Pregnant or breast feeding
Clareo Health | A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
